Five-Year Study: Testosterone Propionate Enhances Aggression, Dominance in U.S. Males
Reading Time: < 1 minute Introduction Testosterone propionate, a short-acting ester of testosterone, has long been a cornerstone in androgen replacement therapy (ART) for hypogonadal American males, comprising approximately 4-5% of men over 45 years according to the Centers for Disease Control and Prevention (CDC). While its anabolic and physiological benefits—such as enhanced muscle mass, libido, and erythropoiesis—are well-documented, its neuropsychiatric ramifications, particularly on social behavior, remain contentious. This five-year longitudinal study investigates the exogenous administration of testosterone propionate (TP) in 1,250 eugonadal and hypogonadal American males aged 35-65, recruited from urban clinics in California, Texas, and New York. We hypothesize that supraphysiological TP levels...








